The promise of nanotechnology for heart, lung and blood diseases

Expert Opinion on Drug Delivery

Volumn 3, Issue 2, 2006, Pages 173-175

  Buxton, Denis ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Cardiovascular; Haemopoietic; Nanotechnology; Pulmonary; Targeted delivery

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CHITOSAN; CYTOTOXIC AGENT; DRUG; FLUOROCARBON; FUMAGILLIN; GADOLINIUM; GELATIN; LIPOSOME; MACROGOL; MONOCLONAL ANTIBODY; PHOSPHATIDYLCHOLINE; POLYMER; PROTEIN; SMALL INTERFERING RNA; SOYBEAN OIL; TRANSACTIVATOR PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUBERCULOSTATIC AGENT;

ATHEROSCLEROTIC PLAQUE; BACTERIAL INFECTION; BALLOON CATHETER; BIOFILM; BLOOD DISEASE; CLINICAL TRIAL; CORONARY STENT; DIAGNOSTIC ACCURACY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG SOLUBILITY; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; DRY POWDER; EDITORIAL; HEART DISEASE; HUMAN; LUNG DISEASE; LUNG INFECTION; LUNG TUBERCULOSIS; LYMPHOCYTE; MATERIAL COATING; MICELLE; MICROENCAPSULATION; MYCOSIS; NANOTECHNOLOGY; NEPHROTOXICITY; NONHUMAN; RESTENOSIS; UNSPECIFIED SIDE EFFECT;

CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; HEMATOLOGIC DISEASES; HUMANS; LUNG DISEASES; NANOTECHNOLOGY; PHARMACEUTICAL PREPARATIONS;

EID: 33644775443     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.3.2.173     Document Type: Editorial

References (10)

1. CYRUS T, WINTER PM, CARUTHERS SD, WICKLINE SA, LANZA GM: Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy. Expert Rev. Cardiovasc. Ther. (2005) 3:705-715.
2. UWATOKU T, SHIMOKAWA H, ABE K et al.: Application of nanoparticles technology for the prevention of restenosis after balloon injury in rats. Circ. Res. (2003) 92:e62-e69.
3. NANAI S, CHORNY M, GERTZ AD et al.: Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials (2005) 26:451-461.
4. PANDEY R, KHULLER GK: Antitubercular inhaled therapy: opportunities, progress and challenges. J. Antimicrob. Chemother. (2005) 55:430-435.
5. PANDEY R, SHARMA A, ZAHOOR A, SHARMA S, KHULLER GK, PRASAD B: Poly (D,L-lactide-co-glycolide) nanoparticles-based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother. (2003) 52:981-986.
6. ZHANG W, YANG H, MOHAPATRA S et al.: Inhibition of respiratory synctial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat. Med. (2005) 11:56-62.
7. KONSTAN MW, DAVIS PB, WAGENER JS et al.: Compacted DNA nanoparticles administered to the nasal mucosa of cystric fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum. Gene Ther. (2005) 15:1255-1269.
8. OTSUBO T, MAESAKI S, HOSSAIN MS et al.: In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus. Antimicrob. Agents Chemother. (1999) 43:471-475.
9. DINAUER N, BALTHASAR S, WEBER C, KREUTER J, LANGER K, VON BRIESEN H: Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials (2005) 26:5898-5906.
10. WANG X, UTO T, SATO K et al.: Potent activation of antigen-specific T cells by antigen-loaded nanospheres. Immunol. Lett. (2005) 98:123-130.